Physician profile
Thomas Ellenberger
NPI 1508818410
$509.19
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $168 · 2021: $187 · 2022: $12.89 · 2023: $12.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $159.41 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $74.53 | 2019-2020 | |
| Lilly USA, LLC | $55.13 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.47 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $47.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.77 | 2019 | |
| Pfizer INC. | $37.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.93 | 2021 | |
| Amgen INC. | $14.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ellenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.